127 related articles for article (PubMed ID: 12006436)
21. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
22. Economic decision analysis model of screening for lung cancer.
Marshall D; Simpson KN; Earle CC; Chu CW
Eur J Cancer; 2001 Sep; 37(14):1759-67. PubMed ID: 11549429
[TBL] [Abstract][Full Text] [Related]
23. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
[TBL] [Abstract][Full Text] [Related]
24. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort.
Marshall D; Simpson KN; Earle CC; Chu C
Lung Cancer; 2001 Jun; 32(3):227-36. PubMed ID: 11390004
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of chest computed tomography after lung cancer resection: a decision analysis model.
Kent MS; Korn P; Port JL; Lee PC; Altorki NK; Korst RJ
Ann Thorac Surg; 2005 Oct; 80(4):1215-22; discussion 1222-3. PubMed ID: 16181843
[TBL] [Abstract][Full Text] [Related]
26. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules.
Edelsberg J; Weycker D; Atwood M; Hamilton-Fairley G; Jett JR
PLoS One; 2018; 13(5):e0197826. PubMed ID: 29787590
[TBL] [Abstract][Full Text] [Related]
28. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
29. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review.
Puggina A; Broumas A; Ricciardi W; Boccia S
Eur J Public Health; 2016 Feb; 26(1):168-75. PubMed ID: 26370440
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of lung cancer screening in Japan.
Okamoto N
Cancer; 2000 Dec; 89(11 Suppl):2489-93. PubMed ID: 11147633
[TBL] [Abstract][Full Text] [Related]
32. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis.
Mooney MM; Mettlin C; Michalek AM; Petrelli NJ; Kraybill WG
Cancer; 1997 Sep; 80(6):1052-64. PubMed ID: 9305705
[TBL] [Abstract][Full Text] [Related]
33. Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare.
Roth JA; Sullivan SD; Goulart BH; Ravelo A; Sanderson JC; Ramsey SD
J Oncol Pract; 2015 Jul; 11(4):267-72. PubMed ID: 25943596
[TBL] [Abstract][Full Text] [Related]
34. The cost effectiveness of radon mitigation in existing German dwellings--a decision theoretic analysis.
Haucke F
J Environ Manage; 2010 Nov; 91(11):2263-74. PubMed ID: 20619957
[TBL] [Abstract][Full Text] [Related]
35. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
[TBL] [Abstract][Full Text] [Related]
37. An economic evaluation of an abdominal aortic aneurysm screening program in Italy.
Giardina S; Pane B; Spinella G; Cafueri G; Corbo M; Brasseur P; Orengo G; Palombo D
J Vasc Surg; 2011 Oct; 54(4):938-46. PubMed ID: 21820837
[TBL] [Abstract][Full Text] [Related]
38. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.
Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A
BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313
[TBL] [Abstract][Full Text] [Related]
39. A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker.
Toumazis I; Erdogan SA; Bastani M; Leung A; Plevritis SK
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34738073
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
